Neural Stem/Progenitor Cell Clones as Models for Neural Development and Transplantation by Hedong Li et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Neural Stem/Progenitor Cell Clones as Models 
for Neural Development and Transplantation 
Hedong Li, He Zhao, Xiaoqiong Shu and Mei Jiang 
West China Developmental & Stem Cell Institute, 
Department of Obstetric & Gynecologic/Pediatric,  
Key Laboratory of Obstetric & Gynecologic,  
Pediatric Diseases and Birth Defects of Ministry of Education, 
West China Second University Hospital, 
Sichuan University, Chengdu, Sichuan Province, 
P.R. China 
1. Introduction 
Neural stem cells (NSCs) are somatic stem cells, capable of giving rise to all the mature cell 
types of the adult nervous system. NSCs are generally “simple” in their cell shape, and 
acquire much more complex morphology as they differentiate into mature cell types. 
Morphological changes are not the only phenomena, both genetic and epigenetic alterations 
also mark the NSC differentiation, allowing development of series of genetic and 
immunological markers to identify and isolate certain cell types from developing neural 
tissue. During early phase of the development of central nervous system (CNS), NSCs 
occupy the newly formed neural tube as a thin layer of cells (called neuroepithelium), which 
later become thicker and more complex in cellular architecture by the process of cell 
proliferation, differentiation, migration and maturation in a precisely organized fashion. The 
underlying mechanisms of these processes are always the attraction to neurobiologists.  
NSC differentiation does not occur overnight; rather, it occurs in a progressive manner 
hypothesized by the lineage-restriction theory. As development proceeds, NSCs acquire 
additional features (demonstrated by markers) and become regionally diversified under the 
influence of gradients of growth factors and cytokines.  These cells still proliferate, but their 
differentiation potential may be limited capable of giving rise to fewer cell types as they 
divide.  This group of dividing cells at any CNS developmental stages is often referred as 
“neural progenitor pool” (Fig. 1). Lineage restriction hypothesis indicates that NSCs 
undergo progressive loss of differentiation potential (i.e. the number of cell types that they 
can give rise to) as neural development proceeds. In support of this notion, certain cell 
surface markers (e.g. A2B5 and 5A5) have been found to label and fractionate lineage-
restricted progenitors of the developing spinal cord in a non-overlapping manner (Mayer-
Proschel et al., 1997). However, lineage restriction is not the only mechanism of NSC 
development. For example, Noble examined the expression patterns of A2B5 and 5A5 in the 
developing forebrain and identified a population of neural progenitors expressing both 
markers suggesting that NSC differentiation is a much more complicated process in the 
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brain than in the spinal cord (Noble et al., 2003). Therefore, the original lineage-restriction 
theory based on the expression of A2B5 and 5A5 may be an oversimplified one and can not 
be generalized to explain NSC differentiation in the entire developing CNS. Nevertheless, it 
initiated a logical prediction, which will be modified or corrected by more upcoming results 
from different area of the developing CNS.  
 
Fig. 1. Immortalized NSPC clones represent neural progenitor diversity during 
development. 
NSCs differentiate at different rate and direction, which creates a diversity of neural 
progenitors at any given period of CNS development. One way to reveal neural progenitor 
diversity is to generate neural progenitor clones (Fig. 1). Over the past decades, numerous 
NSC and neural progenitor clones have been generated, and they have proven to be great 
models in delineating mechanisms of NSC differentiation. Many of these clones have also been 
transplanted into animal models of various neurological diseases and trauma, and 
demonstrated their great usefulness for obtaining mechanistic insights on how exogenous 
NSCs interact with host tissues and promising effects in animal’s behavioural recovery. In our 
laboratory, we also took this approach and generated various neural stem/progenitor cell 
(NSPC) clones from rat embryonic forebrains. In this book chapter, we will review more recent 
discoveries with these “old” and more recently generated neural progenitor clones as in vitro 
models to unravel NSC differentiation mechanisms as well as cellular tools for testing their 
therapeutic potentials in paradigms of transplantation. In the era of translational research, we 
would like to stress on the need for neurobiologists to take on the mission seriously and format 
our thinking to materialize the transition from bench to bedside.  
2. Generation of neural stem/progenitor cell clones 
Neural cell lines have been generated by numerous approaches including isolation from 
spontaneous or induced neural tumors and somatic cell fusion with immortal cells. These 
cell lines have been widely used as in vitro models, some of which we are still 
experimenting on today such as Neuro-2a, PC12 cells. More recently, with the advance of 
our understanding on genetic networks controlling cell proliferation, the “purpose-driven” 
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generation of NSPC clones has been systematically performed. Both growth factor 
stimulation (epigenetic) and viral introduction of immortalizing genes such as oncogenes 
(genetic) have proven to be efficient in generating NSPC clones. In this section, we will 
summarize genetic functions of commonly used immortalizing genes (Myc, neu, large T-
antigen, adenoviral E1A, Tert and p53) in promoting cell proliferation and growth factor 
dependency of the resulting NSPC clones including human NSPC clones (summarized in 
Table 1 below). 
2.1 Immortalizing genes 
Myc has been most extensively studied in cancer research since its deregulation relates 
many different types of tumors (Grandori et al., 2000). Myc also plays a critical role in stem 
cell biology and development where its expression is tightly controlled (Laurenti et al., 
2009). As such, many cancers have been suggested to derive from stem cells during 
development where Myc expression persists or is deregulated into the adulthood. Myc has 
various cellular functions ranging from proliferation, cell growth and differentiation to 
apoptosis. Thirty years after its discovery, the exact molecular mechanisms of Myc 
mediating these functions still remain elusive. As an immortalizing tool, however, Myc has 
been widely used to generate cell lines from different lineages, especially neural cell lines, 
some of which are still widely applied in neuroscience research. 
Myc encodes a transcription factor that binds to E-box sequence CACGTG on genomic 
DNA. Myc protein dimerizes with another bHLH transcription factor Max through its 
bHLH/LZ domain, and its transregulatory domain can interact with numerous co-factors to 
execute its transcriptional activity on target genes including the transcription activator E2F-1 
(Fig. 2). The critical function domains of Myc proteins have been mapped to their N- and C-
terminus, which contain the transregulatory domain and the basic-helix-loop-helix-leucine 
zipper (bHLH/LZ) domain, respectively (Farina et al., 1992; Min et al., 1993; Min and 
Taparowsky, 1992).  
 
Fig. 2. Simplified cellular pathways involving immortalizing genes (labeled in bold). 
www.intechopen.com
 
Neural Stem Cells and Therapy 
 
262 
V-Myc, the viral homologue of cellular Myc (c-Myc), was first discovered from a 
transforming retrovirus MC29 from chicken with spontaneous myelocytomatosis and 
subsequently cloned and sequenced (Alitalo et al., 1983; Reddy et al., 1983; Watson et al., 
1983). V-Myc is expressed as a fusion protein Gag-Myc in MC29 and other related 
retroviruses. Although the Gag portion of the fusion protein seems to be dispensable in its 
transforming activity (Shaw et al., 1985), the first generation of v-Myc containing retrovirus 
for immortalization was created as fusion of v-Myc with part of Gag protein (Villa et al., 2000). 
Myc genes carry mutations, some of which potentiate their transforming activity. A frequently 
detected mutation Thr58 on c-Myc, which is equivalent to Thr61 on v-Myc, is often found in 
Burkitt’s lyphomas where c-Myc was first discovered (Albert et al., 1994). A Thr58 to Ala 
substitution (T58A) in c-Myc has been found to promote its proliferative effect in NSCs, and a 
resulting NSC line immortalized by this mutant c-Myc exhibited enhanced cell proliferation 
compared with NSC line generated by the wild type gene (De Filippis et al., 2008). 
Large T antigen is another popular immortalizing gene used to generate NSC lines. 
Numerous NSC lines have been derived by utilizing different forms of large T antigen (e.g. 
temperature-sensitive and N-terminally truncated mutants) from different regions of the 
developing CNS (Whittemore and Snyder, 1996). SV40 large T antigen is one of the early 
gene products during viral infection by polyomavirus SV40. SV40 is a double-stranded 
DNA virus first identified in 1960 and is responsible for formation of solid tumors upon 
infection. Large T antigen is involved in viral genome replication after infection and 
regulation of host cell cycle mainly through its perturbation of tumor suppressor protein 
p53 and the retinoblastoma protein (pRB) (Fig. 2), although several other cellular factors, 
including the transcriptional co-activators p300 and CBP, may also contribute to its 
transformation function (Ahuja et al., 2005). 
p53 is a tumor suppressor protein and its function is involved in preventing cancer 
formation. P53 plays many cellular roles in its anti-cancer function, which include cell 
cycle regulation, apoptosis and genome stability. Upon activation, p53 can initiate a cell 
cycle arrest to allow DNA repair to take place, or signal cells to go on apoptosis if the 
DNA damage is unfixable. One mechanism of such function of p53 protein is that, upon 
activation, it can turn on the expression of p21, which forms complex with cyclin-
dependent kinase 2 (CDK2) and inhibits its promoting activity in G1/S transition in the 
cell cycle (Wierod et al., 2008) (Fig. 2). Gene knockout of p53 or mutations that affect p53 
binding to DNA results in unavailability of p21 to act as a stop signal in cell cycle. As 
such, cell will continue to divide and in some cases will form tumors. The inactivation of 
p53 can transform cells, and this also provides a way to immortalize cells. Indeed, NSPC 
clones have been reported to derive from p53 knockout mice (Tominaga et al., 2005; 
Yamada et al., 1999), but cautions have to be practiced in using these cells in 
transplantation since they are supposed to be sensitive to DNA mutations and therefore 
more likely to develop tumors in vivo.  
E1A is one of the early gene products of adenoviruses and has also been reported to 
immortalize neural progenitor cells. The primary cellular target of E1A is pRB (Nevins, 
1992). The tumor suppressor protein pRB prevents cell proliferation by inhibiting cell cycle 
progression. Dysfunction of pRB is often detected in many types of cancer. pRB is a member 
of pocket protein family and can bind and inhibit E2F-1 transcription activator, thereby 
preventing cell cycle from entering S phase. Upon adenoviral infection, E1A binds tumor 
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suppressor protein pRB (Fig. 2) and transforms cells with the help of another early gene 
product E1B, which binds p53. 
The oncogene neu was first discovered in a neural tumor, and later was found to share the 
same sequence with human epidermal growth factor receptor 2 (HER2) and avian 
erythroblastosis oncogene B2 (ErbB2). HER2/neu is an oncogene that is involved in many 
types of cancer (Dougall et al., 1994). HER2/neu is a transmembrane receptor tyrosine 
kinase, and it clusters with other members of the EGFR family and initiates signal 
transduction pathways that lead to cell proliferation and differentiation. The downstream 
signaling pathways include the RAS-RAF-MAP kinase, the phosphatidyl inositol 3-kinase 
(PI3K), and the Akt pathways, where RAS-RAF-MAP kinase pathway plays a more 
important role to cell cycle progression, thus neural progenitor immortalization when 
HER2/neu is overexpressed (Fig. 2). Immortalization with neu has been reported 
(Frederiksen et al., 1988; Sherman et al., 1999), but rare.  
Telomerase (Tert) is a reverse transcriptase that adds DNA sequence repeats ("TTAGGG" in 
all vertebrates) to the 3’-end of DNA strands in the telomere regions of chromosome. In 
nearly all dividing mammalian cells, telomere shortening is prevented by the activity of 
Tert, which ensures the sufficient DNA replication during cell division. The decreased 
expression level of Tert accompanied by telomere shortening of chromosome is often 
observed in cells that lose the capacity of cell division and become senescence. 
Overexpression of Tert often leads to cancer formation and also provides a tool for 
immortalization of neural progenitors (Bai et al., 2004; Roy et al., 2004; Schwob et al., 2008) 
(Table 1).  
 
hNSPC clone Tissue origin Immortalizing gene Reference 
B4, C2, C10 and 
others 
13 wks, brain Tet-off v-Myc (Sah et al., 1997) 
HNSC.100 10-10.5 wks, diencephalic 
and telencephalic regions 
v-Myc (Villa et al., 2000) 
hSC11V-TERT 9-13 wks, spinal cord hTERT (Roy et al., 2004) 
hNS2 10 wks, forebrain v-Myc (Villa et al., 2004) 
hNPC-TERT  fetal SVZ (age?) hTERT (Bai et al., 2004) 
CTX0E03 first trimester, brain c-MycER, 
conditional 




8-9 wks, cortex v-Myc (Cacci et al., 2007) 
ReNcell VM  10 wks, midbrain v-Myc (Donato et al., 
2007) 
ReNcell CX  14 wks, cortex  c-Myc (Donato et al., 
2007) 




(De Filippis et al., 
2008) 
hVM1 10 wks, ventral 
mesencephalon 
v-Myc (Villa et al., 2009) 
HB2.G2 11–14 wks, telencephalic 
tissue 
Tet-on v-Myc  (Kim et al., 2011) 
Table 1. Summary of immortalized human NSPC clones. 
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2.2 Growth factor dependency 
Genetic modification such as overexpressing an oncogene in a cell is expected to bypass 
growth factor stimulation and thus make possible the cell cycle progression. In reality, 
however, many neural progenitor cell lines generated by oncogenes mentioned above are 
heavily dependent on growth factors for their in vitro proliferation. Upon removal of these 
growth factors, progenitor cells cease proliferation and go on with differentiation towards 
mature cell types in correlation with the drastic down-regulation of the oncogene expression 
(such as in the case of v-Myc). Although the mechanism of this phenomenon (oncogene 
down-regulation upon growth factor withdrawal) is still unclear (perhaps some type of 
feedback loop system is controlling the exogenous oncogene expression), it provides an 
extremely important safety prerequisite in using these immortalized cells especially in a 
transplantation scenario, since the primary phenotypes of a tumorigenetic cell are growth 
factor independency and loss of contact-inhibition.  
Although some of the early generated neural progenitor lines were propagated in mediums 
containing fetal calf serum (FCS) and sometimes in combination with growth factors, more 
defined serum-free medium has been widely applied in culturing these cells and FCS has 
been used as inducing reagent for differentiation into certain neural cell types such as 
astroglia. Growth factors such as fibroblast growth factor 2 (FGF2) and epidermal growth 
factor (EGF) have been shown to promote proliferation of immortalized neural progenitors 
(Kitchens et al., 1994) and are commonly used in serum-free medium as mitogens to 
promote neural progenitor cell division. In combination of growth factor stimulation and 
immortalizing genes, NSCs can be expanded in large quantity without obvious phenotypic 
abnormalities. Then, upon growth factor withdrawal, NSCs simultaneously differentiate 
along distinct cell lineages. Differentiation inducing factors such as cytokines and 
neurotrophic factors can be applied to facilitate differentiation and survival of certain cell 
types. For example, neurotrophin 3 (NT3) and brain-derived neurotrophic factor (BDNF) 
induce neuronal differentiation and promote neurite outgrowth, while bone morphogenic 
proteins (BMPs) and leukymia inhibitory factor (LIF) induce astroglial differentiation by 
upregulating expression of astrocytic marker, glial fibrillary acidic protein (GFAP). Sonic 
hedgehog homolog (SHH) and platelet-derived growth factor (PDGF) are mitogens to 
subpopulations of neural progenitors and favor differentiation towards oligodendrocyte 
lineage.  
3. Neural stem/progenitor cell clones as in vitro models 
As in vitro models, immortalized neural progenitor clones possess advantages over primary 
cells isolated from tissue. Firstly, one can produce large quantity of immortalized cells 
because of the activity of exogenously introduced oncogenes that keep cell proliferation 
almost infinitely in the presence of appropriate growth factors. Secondly, in vitro expanded 
immortalized progenitors have cellular homogeneity of higher degree than primary cells 
since most of these progenitor clones reported are clonal. Lastly, probably because of their 
promoted cell cycle properties, immortalized progenitor clones are more assessable to 
genetic modification and more likely to maintain gene expression over passages. There are 
excellent reviews in the past categorizing most of these clones and describing scientific 
insights resulted from them (Martinez-Serrano and Bjorklund, 1997; Vescovi and Snyder, 
1999; Whittemore and Snyder, 1996). In this section, we will review more recent works on 
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these clones and new clones generated from our lab and others, and focus on their value as 
in vitro models.  
3.1 Models of neural progenitor development 
Neural progenitors exhibit spatiotemporal diversity during CNS development (Li and Shi, 
2010). To model neural progenitor development, immortalized clones have been isolated 
from different regions of the CNS at different developmental stages (Whittemore and 
Snyder, 1996).  
Hippocampus plays pivotal roles in learning and memory, and is one of the few sites in 
adult CNS that retain the capacity of neurogenesis. Therefore, the proliferation and 
differentiation of hippocampal neural progenitor are of great interests to neurobiologists. 
HiB5 was isolated as a hippocampal neuronal progenitor from E16 rat (Renfranz et al., 
1991), and has been used to model hippocampal neurogenesis. It was found that activation 
of RARgamma promotes proliferation of HiB5 cells in vitro (Chung et al., 2000). When HiB5 
cells were treated with all-trans- or 9-cis-retinoic acid (RA), a significantly increased 
proportion of these cells were found in S-phase. This was accompanied by increased level of 
bcl-2 mRNA, while the level of bax mRNA was not affected, which suggests that retinoid 
treatment increases viable cells by enhancing proliferation rather than suppressing cell 
death. Furthermore, the proliferation promoting effect of retinoid on HiB5 cells can be 
mimicked by RARgamma-selective agonist and blocked by its antagonist (Chung et al., 
2000). HiB5 cells can model differentiation of hippocampal neurons as well. To give an 
example, PKA signalling pathway was examined for its role in hippocampal neuronal 
differentiation process. Kim G et al. demonstrated that treatment of HiB5 cells by cyclic 
AMP (cAMP) in a serum-free medium containing N2 supplement induced drastic neurite 
outgrowth of these cells and inhibition of their proliferation (Kim et al., 2002). 
Phosphorylation of cAMP responsive element binding protein (CREB) was observed 
accompanied by increased expression of neuronal markers including neurofiliments and 
decreased expression of glial markers such as nestin and GFAP. Furthermore, 
overexpression of a GFP-fused protein kinase A (PKA) catalytic subunit alpha protein 
induced neurite outgrowth in HiB5 cells. Altogether, the authors demonstrated the critical 
involvement of PKA pathway in hippocampal neuronal differentiation using HiB5 clone as 
an in vitro model. More recently, another Korean group applied a traditional Korean 
medicine, Scutellaria baicalensis extract, in the culture of HiB5 cells and showed that it 
enhanced cell survival of HiB5 and increased their differentiation into choline 
acetyltransferase (ChAT) positive cholinergic neurons. Along with in vivo data, the authors 
suggested that Scutellaria baicalensis extract might be used as a neuroprotective medicine in 
cerebral ischemia (Heo et al., 2009).  
Hippocampus maintains on-going neurogenesis in the adult CNS, and yet many of the 
newborn hippocampal neurons die shortly after birth especially when brain insults occur. 
Using HiB5 as a model cell, Cacci E et al. were able to show that increased cytokine release 
by activated microglia may contribute to the death of hippocampal neurons (Cacci et al., 
2005). When TNFalpha, as well as conditioned medium from activated microglia, was 
added to the culture medium, HiB5 cells quickly ceased proliferation and underwent 
significant cell death. Both HiB5 and microglia express TNF receptors, TNF-R1 and TNF-R2, 
which may mediate this effect. Hippocampus is vulnerable to different types of insults that 
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lead to neuronal cell death in this brain region. Glucocorticoid (GC), a steroid hormone, 
participates in normal glucose metabolism. However, when high hippocampal GC level is 
prolonged, for example in prolonged stressed condition, hippocampal neurons undergo 
apoptosis. Heat shock protein Hsp27 has been shown to antagonize GC-evoked apoptosis in 
HiB5 cells (Son et al., 2005). When HiB5 cells were treated with dexamethasone (DEX), a 
synthetic GC, apoptosis occurred. Interestingly, expression of Hsp27 was also induced upon 
this treatment. To evaluate possible function of Hsp27 in this process, Son GH et al. 
overexpressed several constructs in HiB5 cells before DEX treatment and demonstrated that 
Hsp27 protects hippocampal neurons from GC-induced apoptosis (Son et al., 2005). The 
same research group also demonstrated that another heat shock protein Hsp25 is involved 
in neuroprotective effect in hippocampal neurons as well. Furthermore, phosphorylation of 
Hsp25 mediated by MAPK and ERK signalling is important for its translocation from 
cytoplasma to nucleus, where it protects nuclear structure, thereby preventing neuronal cell 
death (Geum et al., 2002). P62, a ubiquitously expressed phosphoprotein, is implied to play 
a role in protecting hippocampal neuronal survival. When overexpressed in HiB5 cells, p62 
not only reduces cell death, but also promotes neuronal differentiation of the cells (Joung et 
al., 2005). In addition, pre-treatment by vitamin D3 substantially reduced the degree of DEX-
induced apoptosis in HiB5 and primary hippocampal neurons suggesting a cross-talk 
between vitamin D3 and GC pathways (Obradovic et al., 2006). 
Isolated from rat E14 striatum, neural progenitor clone ST14A has been used as a model for 
striatum-derived neurons (Cattaneo and Conti, 1998). The availability of large number of 
cells made it possible and convenient to examine signalling pathways in these cells. Wnt 
signalling has been shown to involve in NSC differentiation by expressing necessary Wnt 
receptors (Lange et al., 2006). ST14A cells express JAK/STAT signalling components and are 
susceptible to cytokine stimulation leading to cell proliferation (Cattaneo et al., 1996). 
Ventrally born neurons such as cortical interneurons reach neocortex by tangential 
migration. The migratory property of ST14A has been realized and used as a model of 
neuronal migration in vitro. Hepatocyte growth factor /scatter factor (HGF/SF) has been 
involved in migration and proliferation in many types of epithelial cells. HGF/SF and its 
receptor Met are also present in the developing CNS as well as ST14A cells. When ST14A 
cells were exposed to HGF/SF in culture, the cells quickly changed morphology and 
increased cell motility, a process that involves PI3-K pathway as revealed by 
pharmacological blocking analysis (Cacci et al., 2003). The cytoskeletal rearrangement 
including actin network and dissociation of beta-catenin from N-cadherin were also 
observed in ST14A cells upon treatment of HGF/SF, but not nerve growth factor (NGF), 
BDNF, NT3 and ciliary neurotrophic factor (CNTF) (Soldati et al., 2008). ErbB family 
proteins play important function in neuronal migration. Gambarotta et al. demonstrated 
that ErbB4, but not ErbB1-3, is a crucial receptor of neuregulin1 (Nrg1) in activating 
migration of ST14A cells (Gambarotta et al., 2004). By gene expression profiling analysis, the 
same group subsequently identified the epidermal growth factor receptor pathway 
substrate 8 (Eps8), a multimodular regulator of actin dynamics, as a key mediator of 
Nrg1/ErbB4 induced neuronal migration (Fregnan et al., 2011).  
Radial glia (RG) is a transient cell type during CNS development. It is known by their 
unique bipolar radial morphology, which is important for its function of supporting 
neuronal migration. Later, RG has been shown to give rise to neurons and probably the 
major neuronal precursors throughout the developing CNS (Noctor et al., 2002). We 
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generated first RG clones by v-myc immortalization and demonstrated their properties in 
vitro including expression of RG specific markers and ability to support neuronal migration. 
Because of their transient nature, isolation and propagation of RG in vitro have been 
unsuccessful. The v-myc immortalized RG clones (RG3.6 and L2.3) showed high 
proliferation rate in the presence of FGF2 and maintained RG markers over many passages, 
which provides an in vitro model system to allow examination and manipulation on this cell 
type (Hasegawa et al., 2005; Li et al., 2004). We did observe a gradual change in expression 
of certain markers in cultured RG clones during passage. For example, brain lipid binding 
protein (BLBP), a specific RG marker, decreases while a marker for GRPs, A2B5, increases. 
This initial observation eventually led us to discover a transition from RG to restricted 
precursors during embryonic forebrain development (Li et al., 2004; Li and Grumet, 2007). 
To further stablize RG in culture, we introduced actived form of Notch1 into clone L2.3 by 
retroviral infection. We found that active Notch1 signalling inhibited GRP marker 
expression and enhanced RG morphology and gene expression (Li et al., 2008a). 
Among series of neural progenitor clones generated in our lab, clone L2.2 showed neuronal 
restricted differentiation in vitro. Moreover, L2.2 gives rise to exclusively GABAergic 
neuronal subtype upon FGF2 withdrawal as evaluated by their expression of TuJ1, GADs, 
Dlxs and calretinin (Li et al., 2008b). Neurons derived from L2.2 fire action potential in 
culture, and this functional differentiation is accelerated when cocultured with RG clone 
RG3.6 probably through a cell-cell contact mechanism, because the conditioned medium 
from RG3.6 was not able to exert the same effect. The neuronal progeny of RG clone 
identified by TuJ1 positivity exhibits projection neuron phenotypes, e.g., bipolar simple 
morphology, and the majority (87.4 ± 1.5%) of which are glutamate immunoreactive.  Based 
on our gene expression analysis, L2.3 differentiated culture also expressed T-brain-1 (Tbr-1) 
transcription factor, which, along with Pax-6 and Tbr-2, is an essential marker for projection 
neuron differentiation in vivo (Hevner, 2006). During cortical neurogenesis, most, if not all, 
of glutamatergic projection neurons come from RG, which later differentiate into glial cells. 
Therefore, clone L2.2 and L2.3 (or RG3.6) generate interneurons and projection neurons, 
respectively in culture, and they may serve as in vitro models to study interaction between 
these different neuronal subtypes during cortical development. 
3.2 Gene profiling and high-throughput analysis 
The availability of large quantity of cells by in vitro expansion of immortalized neural 
progenitors made large-scale analysis possible. For example, gene expression profiling 
experiment using ST14A cells overexpressing GDNF has revealed upregulated genes that 
are involved in neural differentiation and migration (Pahnke et al., 2004). ST14A cells 
overexpressing CNTF demonstrated increased proliferation, metabolic activity and 
resistance to stress during early differentiation (Weinelt et al., 2003). Similarly, gene 
expression profiling analysis confirmed this observation by showing upregulated genes that 
are involved in stress response pathway of this CNTF-ST14A cells (Bottcher et al., 2003). By 
overexpressing activated Notch1 gene in RG clone L2.3, we generated a new clone NL2.3 
that exhibits enhanced RG marker expression and exaggerated RG morphology (Li et al., 
2008a). To explore genes that are responsible for RG phenotype, we conducted gene 
expression comparison between NL2.3 and its parental clone L2.3. As expected, RG related 
genes such as BLBP, nestin, tenasin and vimentin were upregulated in NL2.3, and 
surprisingly we also found that cell adhesion molecules, especially nidogen1 (showing 50 
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fold increase comparing to L2.3), were upregulated, which may explain the better 
attachment of NL2.3 cells on laminin-coated substrate. We further confirmed the functional 
role of nidogen1 in mediating cell adhesion by antibody blocking experiments, and revealed 
a previously unrecognized link between Notch1 signalling and cell adhesion. In addition, 
we showed that primary RG cells also express nidogen1 in a secreted fashion demonstrating 
the physiological significance of this result (Li et al., 2008a).  
Proteomics in NSCs is still in its early stage. Nevertheless, large quantity of cells from 
immortalized progenitors is well suited for this type of analysis. Clone ST14A and an 
immortalized human NSC clone ReNcell VM have been applied in 2-DE proteomic profiling 
leading to meaningful discoveries (Beyer et al., 2007; Hoffrogge et al., 2007). Another 
significant application of expandable neural progenitor cells is high throughput (HTP) 
screening. Beside drug screening in neural progenitors in pharmaceutical industry, there is 
also an increasing demand for HTP protocol for genetic analysis on a genome scale. Park JY 
et al. developed two HTP-optimized expression vector systems that allow generation of red 
fluorescent protein (RFP)-tagged target proteins (Park et al., 2007). Using these systems, the 
authors screened sixty representative human C2 domains for their neuronal promoting 
effect, and identified two C2 domains for their further study. This is another good example 
for taking advantages of large quantity of cells from immortalized NSC clones.  
3.3 Models for neurological diseases 
NSC clones are capable not only to facilitate research on NSC differentiation, but also 
provide model systems for neurological diseases. Here, we give an example on clone ST14A. 
Derived from embryonic striatum, ST14A cells have been used as in vitro model for 
Huntingtin’s disease (HD). In fact, it has been shown that under serum-free condition, 
ST14A cells were able to differentiate into DARPP-32-positive medium spiny neurons 
spontaneously and displayed electrophysiological properties similar to those of medium 
spiny neurons (Ehrlich et al., 2001). Protein aggregation is the hallmark of 
neurodegenerative diseases including HD. Ossato G et al. developed a so-called number 
and brightness method to monitor aggregation of Huntingtin exon 1 protein directly in live 
ST14A cells and found that the mutant protein underwent a two-step aggregation process, 
an initial phase of monomer accumulation and oligomer formation followed by protein 
inclusion depleting monomers in the cytoplasma (Ossato et al., 2010). The pathology of HD 
has been well documented, and yet its underlying molecular mechanisms still remain 
elusive. Using the same clone, Sadri-Vakili G et al. demonstrated that epigenetic regulation 
plays a role in HD progression (Sadri-Vakili et al., 2007). It was found that despite no change 
in overall acetylated histone levels, histone H3 was hypo-acetylated at the promoter regions 
of certain down-regulated genes in ST14A cells as well as in R6/2 mice, an animal model for 
HD. Furthermore, histone deacetylase (HDAC) inhibitor treatment increased level of 
acetylated histones and seemed to correct expression of misregulated genes, suggesting a 
potential therapeutic application of HDAC inhibitors for HD (Sadri-Vakili et al., 2007). 
Altered cholesterol biosynthetic pathway has been reported to involve in HD. The 
expression level of several key genes in the cholesterol pathway is severely disrupted in 
brain tissues of HD mice and human patients (Valenza et al., 2005). Mutant Huntingtin was 
introduced into ST14A cells and it significantly reduced total cellular cholesterol mass. By 
adding cholesterol back to the cells, the authors were able to prevent cell death of mutant 
ST14A in a dose-dependent manner. This report uncovered the cholesterol pathway as a 
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novel player in HD, which could be used as a potential target for HD treatments. 
Phosphorylation of Huntingtin protein appears to be protective in HD, which is mediated 
by phosphatase calcineurin and phosphokinase Akt. Regulator of calcineurin (RCAN1-1L) is 
suppressed in HD patient samples, and overexpression of RCAN1-1L in ST14A cells that 
contain mutant Huntingtin gene increases phophorylation of Huntingtin and reduces ST14A 
cell death (Ermak et al., 2009). Therefore, the authors claim that RCAN1-1L might be a 
mediator for HD progression and offer an alternative avenue for drug treatments. 
3.4 Testing biomaterials 
Biomaterial science has been a fast-growing field providing promising materials for tissue 
engineering. Biocompatibility of these materials is a big issue since they will be in contact 
with human cells and tissue. Large quantity of cells, especially cells derived from 
immortalized neural progenitors are well suited to test toxicity of biomaterials to cells in 
culture, because in many cases, transplantation of neural progenitor cells is accompanied by 
biomaterials in the hope that the latter can potentiate stem cell differentiation and migration. 
The biocompatibility of a variety of biomaterials including polymers and nanofibers were 
tested using immortalized progenitor cells as first step towards biological applications. 
Poly(lactic-co-glycolic acid) (PLGA) was compared with other types of polymers in 
culturing with clone HiB5, where it performed the best in terms of supporting cell viability 
and neurite outgrowth. This result provided evidence that PLGA could be used as a scaffold 
for NSC transplantation for nerve regeneration (Bhang et al., 2007). Polymers can also be 
created to have different patterns and dimensions by various means. Electrospun poly(l-
lactide) (PLLA) fibers with different parameters were tested in culture with NSPC clone 
C17.2. The cells displayed significantly different growth and differentiation depending on 
fiber pattern and dimension they adhered (He et al., 2010). PLLA can also be modified by 
tethering laminin-deirved peptides through a cross-linking reagent, and the modified PLLA 
showed significant improvement in supporting cell survival and neurite outgrowth of C17.2 
cells (He et al., 2009). A UV pre-irradiation followed by UV grafting technique can create 
gradients of carboxyl group on poly(acrylic acid) (PAA) substrates. It was shown that C17.2 
cells adhered to these substrates and appeared to respond the carboxyl gradient by 
directionally sending out neurites (Li et al., 2005). Polymers modified to be electronic 
affected seeding density of C17.2 cells and may have effects on stem cell differentiation as 
well (Salto et al., 2008). This report provided an alternative electronic control over NSC 
differentiation. 
Nanotechnology has revolutionized the biomaterial field. Polymers and scaffolds produced 
at nano-scale have proven to be superior than other material in biological applications. 
Biomaterials made by nanopolymers possess high surface-to-volume ratio and offer a 
variety of topographic features that may promote cellular behavior. Nanofibrous scaffolds 
fabricated with different ratios of poly(epsilon-caprolactone) (PCL) and gelatin were tested 
in their ability to promote neuronal differentiation of C17.2 cells, and the PCL/gelatin 70:30 
ratio generated the best biomaterial suited for nerve regeneration (Ghasemi-Mobarakeh et 
al., 2008). Similar cell culture tests were also performed on electroconductive polymeric 
nanowire templates showing that polypyrrole coating improved their effects on cell 
adhesion and proliferation (Bechara et al., 2011). 
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4. Neural stem/progenitor cell clones for transplantation 
The promise for stem cells including NSCs is someday they may be used as therapeutic 
cures for diseases. In animal models, there are numerous reports that support this promise 
and demonstrate great potential of these cells in tissue protection, replacing lost cells and 
restoring behavioural function when transplanted in a variety of diseases and trauma. 
Immortalized NSCs provide unlimited cell number and maintain stem cell characteristics such 
as differentiation potentials to certain cell lineages, and therefore are outstanding candidates 
for this purpose. Attempts have been made for NSCs to go into human patients hoping they 
behave similarly to transplanted cells in animals. However, the major concern is the safety of 
these cells. NSCs derived from either primary tissue or immortalized counterparts have 
tendency to form tumors upon transplantation since their cell cycle dynamics have been 
altered by stimulation of growth factors and/or exogenous oncogenes in the case of 
immortalized NSCs. Although researchers have claimed that some of the oncogenes are non-
transforming (e.g. Myc) and their expression is drastically reduced after NSC differentiation 
and transplantation in vivo, precautionary measures have to be taken into practice to ensure 
the safety of these cells in clinical settings. In this section, we will review up-to-date reports 
from others’ work on transplantation using immortalized neural progenitor clones in normal 
and diseased CNS. We will also describe our work using neural progenitor clones to treat 
spinal cord injury in rat. Finally, we will touch on tumor inhibition, an unexpected property of 
NSCs revealed by studies using immortalized NSPC clones.  
4.1 Transplantation into normal CNS 
In order for NSCs to fulfil neural reparative goal, a key property is to be able to differentiate 
into mature cell types in regions of transplantation. Neurogenesis and neuronal 
differentiation are already completed in most regions of the adult brain. Therefore, it is a bit 
of challenge for transplanted cells to differentiate under this “mature” environment. 
Surprisingly, however, permissive cues must be still present in neonatal and adult CNS 
allowing neuronal differentiation to occur. Immortalized NSCs have been transplanted first 
into normal animals and tested in their survival, migration and differentiation potentials 
under in vivo environments. For example, RN33B, a conditionally immortalized neural 
progenitor clone derived from E13 rat medullary raphe nucleus (Whittemore and White, 
1993), was transplanted into various regions of neonatal and adult brains. In cerebral cortex 
and hippocampus formation, RN33B cells survived up to 24 weeks and differentiate with 
morphologies similar to pyramidal neurons, granule neurons and polymorphic neurons in a 
region-specific manner (Shihabuddin et al., 1995). Electron microscopy and 
immunohistochemistry demonstrated that differentiated RN33B cells received synapses 
from host neurons. In striatum, transplanted RN33B cells survived, integrated and 
differentiated into neurons and glia, some of which displayed morphological and 
phenotypic properties of medium-sized spiny neurons. These neurons were also found to 
form connections with primary striatal target, the globus pallidus, by retrograde tracing 
analysis (Lundberg et al., 1996). Furthermore, GFP-labelled RN33B cells transplanted into 
hippocampus exhibited remarkable neuronal morphology and were capable of firing action 
potentials and receiving synaptic inputs of both excitatory and inhibitory nature (Englund et 
al., 2002). In contrast to neuronal differentiation mentioned above, RN33B cells transplanted 
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in the mesencephalon predominantly differentiated into astroglia (Lundberg et al., 2002). 
These observations suggest that regional cues are still present in the adult brain that can 
direct differentiation of transplanted neural progenitors into certain cell types, which can 
integrate into local tissue structures, although it has been shown that neonatal brains have 
greater capacity to encourage differentiation, especially neuronal differentiation, of 
transplanted cells than adult brains suggesting a decline of permissive cues during CNS 
development (Shihabuddin et al., 1995).  
On the other hand, immortalized progenitors derived from one region of the brain can 
differentiate into cell types specific to the other indicating plasticity of these cells that may 
broaden their reparative application in different areas of the CNS. Indeed, when RN33B, 
along with another NSPC clone C17.2 derived from postnatal cerebellum, was 
transplanted into adult retina, they survived up to 4 weeks and differentiate into both 
neurons and glia in all major retinal cell layers including retinal pigment epithelium 
(Warfvinge et al., 2001). Intrinsic molecular natures of individual progenitor clones have 
to be considered when applying them into transplantation therapies. They all may be 
multipotent in culture, but have limited potentials to differentiate in vivo. For example, 
two weeks after transplantation into adult striatum, unlike RN33B cells to become both 
neurons and glia, clones HiB5 and ST14A differentiate mostly into glial cells (Lundberg et 
al., 1996), indicating their distinct intrinsic properties including possible distinct 
responsiveness to the local host environment. Worthy of noting is that these NSC-derived 
astroglia functionally integrated into host by showing reactive phenotype in response to 
brain damage (Lundberg and Bjorklund, 1996). By using immortalized NSC clones, the 
above mentioned results demonstrated the plasticity of NSCs to differentiate into distinct 
cell types by responding to local cues, and the fact that adult brains still retain, to a certain 
degree, the ability to direct differentiation of exogenous neural progenitor cells. C17.2 
cells were also transplanted into lumbar region of normal spinal cord where they 
differentiated into nonmyelinating ensheathing cells. In addition, they appeared to induce 
host axons to form de novo tracts aiming at graft site probably through the action of their 
secreted neurotrophic factors, suggesting NSCs may also trigger regenerative potentials of 
host tissue needing for repair (Yan et al., 2004). 
4.2 Neurodegenerative diseases 
Neurodegenerative diseases are caused by region-specific, progressive cell death and 
include Parkinson’s disease (PD), HD, Alzheimer’s disease (AD) and amyotrophic lateral 
sclerosis (ALS). This is an area where cell replacement therapies are on high demand. We 
will take PD as an example to highlight the value of immortalized progenitors in testing 
effects of NSCs in PD animal models in terms of neuroprotection and differentiation into 
desired neuronal cell type. The common pathology of PD patients is the progressive loss 
of dopaminergic neurons in the substantial nigra that normally project axons onto 
striatum. As a result, dopamine level in the striatum greatly reduced, which is believed to 
induce PD symptoms such as dystonic cramps and dementia (Weidong et al., 2009). 
Attempts have been made to restore dopamine level by various means, which seem to 
alleviate symptoms to a certain degree, but they can not prevent PD progression and 
replenish the lost neurons.  
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Clone C17.2 has been transplanted into normal and lesioned striatum of the adult rat brain 
in testing their behaviour in local environment where dopaminergic neurons reside. 
Consistent with the notion mentioned above, these cells were able to turn on neuronal 
markers and tyrosine hydroxylase (TH), an enzyme critical to dopamine systhesis, 
suggesting that local cues are still present and powerful enough to direct multipotent 
immortalized NSCs to differentiate into local neuronal subtypes (Yang et al., 2002). Efforts 
have also been made to reinforce dopaminergic differentiation of transplanted progenitors 
to maximize their effects in PD animal models. For example, C17.2 cells have been 
genetically modified to overexpress enzymes (e.g. TH and GTP cyclohydrolase 1) (Ryu et al., 
2005), Nuclear receptor related 1 protein (NURR1) (Li et al., 2007) and secreted factors (e.g. 
neurturin) (Liu et al., 2007) towards the goal of getting more dopaminergic neurons. Both 
TH and GTP cyclohydrolase 1 are required for efficient L-DOPA synthesis, since HPLC 
assays demonstrated that L-DOPA released from C17.2 cells that are transduced with both 
genes (C17.2-THGC) is 760-fold higher than that from C17.2 cells transduced with TH gene 
alone (C17.2-TH). Following transplantation into striatum of PD rats, C17.2-THGC was able 
to promote animals’ behavioural improvement when compared with transplants with 
parental C17.2 cells (Ryu et al., 2005). NURR1 has been shown to induce downstream target 
genes such as TH and facilitate dopaminergic differentiation. When overexpressed in C17.2 
cells, NURR1 enhanced cell differentiation into dopaminergic neurons and even promoted 
behavioural recovery to a certain extent (Li et al., 2007). Unlike in normal CNS, transplanted 
neural progenitors have to overcome unfavourable environment in diseased tissue to 
survive and differentiate. Therefore, manipulations that mitigate local environment may 
prove to facilitate beneficial outcomes. Neurturin is a secreted factor that belongs to glial 
cell-derived neurotrophic factor (GDNF) family. Like GDNF, neurturin exerted 
neuroprotective effects on host dopaminergic neurons after transplantation into lesioned 
striatum. In addition, neurturin also promoted dopaminergic differentiation of C17.2 cells 
when overexpressed, and animal behaviour as well (Liu et al., 2007). Similarly, interleukin-
10 overexpression in C17.2 lowered immune response of host tissue to create a beneficial 
microenvironment for cell survival and differentiation (Wang et al., 2007). In addition, 
treatment of melatonin in combination with C17.2 showed neuroprotection in PD models 
(Sharma et al., 2007). 
4.3 Brain and spinal cord injury 
Traumatic brain injury (TBI), also called acquired brain injury or simply head injury, occurs 
when a sudden trauma causes damage to the brain. TBI can result when the head suddenly 
and violently hits an object, or when an object pierces the skull and enters brain 
tissue. Symptoms of a TBI can be mild, moderate, or severe, depending on the extent of the 
damage to the brain. Besides direct damage of brain tissue by trauma, secondary damage in 
TBI results from toxic effects of a variety of modulators that magnify the initial traumatic 
damage. Among these modulators are the excitatory transmitter glutamate, the intracellular 
messenger calcium, and the intercellular messenger nitric oxide. Glutamate-induced 
toxicity, also called excitotoxicity, occurs from excess glutamate release following trauma. 
Because of the very limited capacity of the brain for self-repair, cellular transplantation has 
been explored to improve repair. The goal of many studies has been to replace the lost 
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neurons (Bjorklund, 2000; Gage, 2000; Lie et al., 2004; McKay, 1997). Although instructive 
cues for neuronal differentiation in normal adult brains seem still exist (albeit declining 
comparing to neonatal brains), the local environment around the injured brain region could 
be very different. Transplanted cells have to overcome extra hurdles such as glutamte 
excitotoxicity and high concentration of released cytokines to survive and differentiate. 
Nevertheless, studies in the past have shown that immortalized progenitors can survive and 
differentiate upon transplantation in TBI. C17.2 cells were injected into adult mouse brains 
at 3 days after lateral controlled cortical impact injury (Riess et al., 2002). The study 
demonstrated cell survival of C17.2 as long as 13 weeks post-transplantation and significant 
improvement in motor behavior of C17.2 transpalnted animals as compared with those 
received human embryonic kidney cells. It was also found in this study that C17.2 cells 
implanted contralateral to the impact side differentiated into mostly neurons, while the cells 
implanted ipsilateral to the impact side differentiated into astroglial cells as well as neurons 
consistent with the notion that injured environment favors glial differentiation of transplanted 
NSCs (Riess et al., 2002). In order to improve the efficacy of NSC mediated beneficial effects in 
TBI treatemnt, immortalized progenitors engineered to express neurotrophic factors have been 
utilized. As expected, these genetically modified cells showed neuroprotective effects and 
improved functional recovery of the animals. For example, C17.2 overexpressing GDNF 
(GDNF-C17.2) improved survival of transplanted cells, enhanced neuronal differentiation of 
these cells and promoted learning behavior of the TBI rats at 6 weeks after transplantation 
comparing to parental C17.2 cells (Bakshi et al., 2006). Similarly, HiB5 progenitor clone 
engineered to secrete NGF (NGF-HiB5), when transplanted peripheral to the TBI site, 
decreased apoptosis of the host hippocampal neurons and improved motor and cognitive 
function comparing to controls (Philips et al., 2001).  
Spinal cord injury (SCI) is a severe CNS injury often resulting in long-term disability. 
Immediately after contusion there is limited histological evidence of damage followed by 
neuronal death (hours), and that is followed by macrophage infiltration, Wallerian 
degeneration and astrogliosis (days-weeks). Similarly to TBI, physical disruption of spinal 
cord causes membrane depolarization and results in massive glutamate release, which is not 
only excitotoxic to injured cells themselves but surrounding cells. Several weeks after 
contusion injury in humans as well as in rats (but not in mice), cystic cavities develop 
surrounded by gliotic scars associated with extracellular matrix including chondroitin sulfate 
proteoglycans (CSPG), which is not hospitable to axonal regeneration (Busch and Silver, 2007).  
Advances in cell characterization and isolation are opening new opportunities for cell 
transplantation to repair tissue damage by replacing cells that restore lost function (Gage, 
2000). Numerous immortalized NSCs have been implanted into SCI to test their 
differentiation potentials and efficacy on functional recovery. Embryonic raphe nucleus-
derived progenitor clone RN33B morphologically differentiated into multipolar neurons 
resembling nearby endogenous ones when transplanted into gray matter of normal spinal 
cord. However, only relatively undifferentiated RN33B cells with bipolar morphology could 
be found at 2 weeks after transplantation into rat spinal cords with various types of injuries 
with depletion of endogenous neurons due to the lesions. The authors suggested that cell-
cell contact mechanisms contribute to instructive local cues for permissive neuronal 
differentiation of transplanted progenitors, and that molecules released from the injury site 
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may also have prevented these cells from becoming neurons (Onifer et al., 1997; 
Whittemore, 1999). On the other hand, implanted neural progenitors secrete neurotrophic 
factors themselves, which may alter the microenvironment they encounter inside the CNS 
tissue. Clone C17.2 cells have been shown to naturally express and secrete several trophic 
factors including NGF, BDNF and GDNF both in vitro and in vivo after transplantation (Lu 
et al., 2003). When implanted into adult rat spinal cords with cystic dorsal column lesion, 
C17.2 cells promoted extensive growth of endogenous axons. Elevated expression of one 
factor NT3 by genetic modification in C17.2 expanded this promoting effect (Lu et al., 2003), 
and improved C17.2 cell survival near the lesion site and functional recovery analyzed by 
Basso-Beattie-Bresnahan (BBB) scoring (Zhang et al., 2007). We reported that an 
immortalized neural progenitor clone sharing properties with NSPC and radial glia (RG3.6) 
migrated extensively in the injured rat spinal cord and improved open field walking when 
transplanted acutely following contusive SCI (Hasegawa et al., 2005).  The transplanted 
RG3.6 cells partially protected the rat spinal cord against several aspects of secondary injury 
including loss of axons and myelin as well as accumulation of CSPG and macrophages 
(Hasegawa et al., 2005).  
Patients with SCI not only lose motor function below the injury site, but often develop 
debilitating neuropathic pain (allodynia) over time (Siddall et al., 1999), which diminishes 
the quality of their lives. The mechanisms underlying allodynia may be very complex and 
many possible factors contribute to these symptoms (Hulsebosch, 2005). One direct factor is 
the loss or reduction of inhibitory tone in the spinal cord sensory processing due to injury. 
Therapeutic strategies that prevent induction of allodynia, such as cell transplants that 
release anti-nociceptive substances, can be used to enhance the endogenous descending 
inhibitory neurotransmitter systems, such as GABA and serotonin (5HT). Immortalized 
progenitor RN33B cells were therefore used as a vehicle to deliver GABA in SCI. RN33B 
cells overexpressing GAD67, an enzyme critical for GABA synthesis, were transplanted into 
lumbar subarachnoid space of the rat spinal cord with chronic constraint injury (CCI) (Eaton 
et al., 1999b). Seven weeks after transplantation, RN33B cells were found on the pial surface 
of the spinal cord, and the animals that received these cells showed significantly reduction 
of both tactile and temperature allodynia comparing to those that received control cells. In 
the same CCI injury model, RN33B cells overexpressing BDNF or galanin have also been 
shown to have beneficial effects in reducing allodynia (Cejas et al., 2000; Eaton et al., 1999a). 
When C17.2 NSCs were transplanted into injured spinal cord, they primarily differentiated 
into astrocytes, which may result in sprouting of dorsal horn nocioceptive neurons and in 
turn allodynia of the animals. GDNF, when overexpressed in transplanted C17.2 cells, 
reduced nocioceptive fiber sprouting and allodynia to a certain extent suggesting a 
protective or analgesic effect of GDNF on injury-induced neuropathic pain (Macias et al., 
2006). We have isolated cortical GABAergic interneuron progenitor clones from rat 
embryonic forebrains and demonstrated their restricted interneuronal differentiation in 
culture. We are further testing these intrinsic GABAergic progenitor clones in vitro and after 
transplanation in SCI, hoping that the cells can differentiate into neurons with GABAergic 
phenotype in SCI, not only to release GABA to reduce allodynia, but also to integrate into 
local neuronal circuitry and permanently eliminate the pain-like syndrome. Towards that 
goal, we have demonstrated that one such clone exhibited spontaneous synaptic activity 
when cocultured with E17 hippocampal neurons (Li et al., 2011).  
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4.4 Tumor inhibition 
One surprising and yet interesting feature of NSCs when implanted in vivo is their ability to 
target tumorous tissues and inhibit their growth. For example, immortalized neural 
progenitor clones isolated from different regions of the embryonic brain, HiB5 
(hippocampus) and ST14A (striatum primordium), were transplanted into nucleus 
Caudatus of Fisher rats along with N29 glioma cells. Both progenitors exhibited anti-tumor 
activity and prolonged animal’s survival. Clone HiB5 was also shown to inhibit an 
additional tumor type and even be effective when transplanted 1 week after tumor cells 
inoculation (Staflin et al., 2004). Clone C17.2 was also tested in their tumor-tropic capacities 
in a similar paradigm, and the results showed that these cells were able to inhibit tumors of 
both neural and nonneural origin (Brown et al., 2003). Furthermore, C17.2 cells were able to 
migrate into the tumor mass even when injected via peripheral vasculatures showing great 
homing capacity of these cells that can be used to deliver therapeutic agents. The 
mechanism of the NSC homing phenomena towards tumor is not very clear. C17.2 
chemotactic migration was tested in vitro by conditioned medium prepared from glioma 
culture as well as 13 different tumor-associated growth factors (Heese et al., 2005). The 
results showed that scatter factor/hepatocyte growth factor (SF/HGF) was the most potent 
one in attracting C17.2 cells in culture. In addition, antibody against SF/HGF was able to 
block the migratory behaviour of these cells stimulated by glioma-conditioned medium. 
Furthermore, Allport JR et al. showed tumor-targeting acivity of C17.2 in vivo and identified 
two other factors that are involved in this NSC homing event (Allport et al., 2004). This 
study showed that C17.2 cells that were transduced to express luciferase (C17.2-luc) 
accumulated onto tumors in mice carrying Lewis lung carcinomas. In vitro analysis showed 
that accumulation of C17.2-luc cells on tumor-derived endothelium (TEC) can be inhibited 
by functional blocking antibodies against SDF-1alpha and CD49d suggesting the 
involvement of SDF-1alpha/CXCR4 receptor and alpha4-integrin in the recruitment of 
C17.2-luc cells (Allport et al., 2004).  
Unlike C17.2, HiB5 cells have not been able to show homing capacity towards tumors, even 
though HiB5 cells exhibited growth-inhibitory effect when they were cotransplanted with 
tumor cells into animals. Honeth et al. introduced the chemokine receptor CXCR3 to HiB5 
cells and demonstrated its functionality by responding to ligand stimulation and activating 
downstream signaling pathways such as ERK and SAPK/JNK (Honeth et al., 2006). Upon 
transplantation, these modified cells showed enhanced migration towards glioma that 
expressed CXCR3 ligands, IP-10 and I-TAC, in comparison with parental HiB5 cells. This 
study provided proof-of-concepts that immortalized progenitors can be genetically modified 
and acquire homing capacity towards tumor to either inhibit tumor growth on its own or 
deliver therapeutic agents for local treatments. Among good examples of this notion is the 
study that was carried out by Barresi V and colleagues, where they genetically engineered 
neural progenitor clone ST14A to express cytosine deaminase (CD), by which 5-
fluorocytosine (5-FC) can be converted into 5-fluorouracil (5-FU) to suppress tumor growth. 
DiI prelabeled CD-expressing ST14A cells were cotransplanted into rat brains with C6 
glioma. The data showed that ST14A cells survived inside C6 tumor mass for at least 10 
days and significantly reduced the size of tumor comparing to controls presumably through 
the action of 5-FU (Barresi et al., 2003).  
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5. Conclusions and perspectives 
NSCs hold enormous promises for treating neurological diseases. However, at the present 
time, we are still facing many hurdles, one of which is how to direct these multipotent cells 
to become the desired cell types for a certain disease. NSPC clones proliferate rapidly in 
culture and maintain certain important characteristic properties after passages, therefore 
provide invaluable models for in vitro studies and transplantable tools for testing 
hypothesis in treating neurological disorders. Immortalized neural progenitor clones are 
potentially tumorigenic since they are engineered to express oncogenes such as Myc. Even 
though many reports have demonstrated that Myc expression is growth factor-dependent 
and can be down-regulated to an undetectable level after FGF2 withdrawal both in vitro and 
after transplantation, cautions have been taken to ensure the shutdown of oncogene 
expression upon cell differentiation. For example, modified immortalizing oncogenes such 
as the temperature-sensitive mutant of large T antigen, tsA58, have been used to generate a 
series of neural progenitor clones from the developing CNS. The tsA58 gene product is 
stable at permissive temperature (33ºC), but rapidly degraded when temperature goes 
higher such as body temperature in culture as well as after transplantation into animals. 
Generation of neural progenitor clones using controllable-Myc expression may provide 
another solution to the same problem. Human NSPC clones (summarized in Table 1) have 
been generated by tetracycline-controllable v-Myc (Kim et al., 2011; Sah et al., 1997) and c-
MycERTAM transgene (Pollock et al., 2006). On the other hand, functions of promoting 
proliferation and tumorigenesis can be uncoupled in an experimental setting (Johnson et al., 
2008). Therefore, dissecting out functional domains of oncogenes that enable sufficient 
expansion of neural stem cells and limit (or eliminate) their tumorigenic activity will be 
advantageous to generate newer version of immortalizing reagents (Harvey et al., 2007; 
Truckenmiller et al., 2002). A recent report on induced pluripotent stem cells (iPSCs) 
indicated that L-Myc, a Myc gene isoform, promoted iPSC generation with little 
transformation activity (Nakagawa et al., 2010). These safety-oriented designs in generation 
of immortalized progenitors will prove to be crucial in minimizing tumorigenc potential of 
exogenous oncogenes, and more research should be performed to optimize NSC 
immortalizing techniques especially in regard to safety for future clinical applications.  
Oncogenes that are frequently used for NSC “immortalizations” such as Myc, carry 
mutations and are prone to spontaneous mutation as well. Some of these mutations 
potentiate their ability of transformation and tumorigenesis. Therefore, the culturing 
conditions for in vitro expansion of immortalized NSC clones need to be optimized and 
controlled in the goal of less stress so that spontaneous mutations can be minimized. The 
low oxygen culture condition, which many researchers have applied in their human stem 
cell culture, would fit in this type of precaution in addition to the fact that NSCs grow and 
differentiate better under this condition. Furthermore, a “quality check” protocol needs to be 
developed to screen out and eliminate cells with such mutations and tumor-like growth 
patterns in the case where mutations do occur. Stem cell replacement therapy is at its 
“transforming” stage. We are very hopeful for its future, but a lot more work needs to be 
done before it can go on to clinic, especially in regard to safety. Nevertheless, immortalized 
NSPC clones will for certain be the milestones in the road towards the ultimate goal of stem 
cell replacement therapy and, in some instances, may very well become therapeutics 
themselves (Thomas et al., 2009).  
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